论文部分内容阅读
目的观察应用阿司匹林肠溶片和硫酸氢氯吡格雷片在预防心脑血管系统疾病的发病风险中的比较。方法选择2005年5月至2010年7月来本院门诊就诊和住院的有冠状动脉粥样硬化病史和心绞痛发作史以及暂时性脑缺血发作史患者共698人,把上述患者随机分成两组,治疗组368人服用阿司匹林肠溶片,对照组330人服用硫酸氢氯吡格雷片。结果治疗组在降低心脑血管系统疾病患者发病风险中的复发率为2.44%,而对照组为2.42%,差异无统计学意义。治疗组和对照组均有一人颅内出血,治疗组有3人消化道出血,对照组2人消化道出血,不良反应的发生率也无显著性差异。但药品费用的支出氯吡格雷片为阿司匹林肠溶片的几十甚至几百倍。结论阿司匹林肠溶片和硫酸氢氯吡格雷片在降低心脑血管系统发病风险中的作用无显著性差异,不良反应的发生率也无显著性差异,但药物经济学方面差异显著。
Objective To compare the incidence of aspirin enteric-coated tablets and clopidogrel hydrogen sulfate tablets in the prevention of cardiovascular and cerebrovascular diseases. Methods A total of 698 patients with history of coronary atherosclerosis, history of angina pectoris and transient ischemic attack from May 2005 to July 2010 in our outpatient department were randomly divided into two groups 368 in the treatment group took aspirin enteric-coated tablets and 330 in the control group took clopidogrel hydrogen sulfate tablets. Results The recurrence rate of the treatment group in reducing the risk of cardiovascular and cerebrovascular diseases was 2.44%, while the control group was 2.42%, the difference was not statistically significant. One patient in the treatment group and the control group had intracranial hemorrhage. In the treatment group, 3 patients had gastrointestinal bleeding and 2 patients in the control group had gastrointestinal bleeding. The incidence of adverse reactions was also not significantly different. However, the cost of drug costs of aspirin tablets for aspirin tablets dozens or even hundreds of times. Conclusions There is no significant difference between the aspirin enteric-coated tablets and clopidogrel bisulfate tablets in reducing the risk of cardiovascular and cerebrovascular diseases. There is no significant difference in the incidence of adverse reactions, but there are significant differences in the pharmacoeconomics.